EcoDrugPlus

5'-Nucleotidase Ecto

Ensembl ID : ENSBBBG00000021770
Gene Symbol: NT5E
3 Cross references
250 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSBBBG00000013967
Gene Symbol: HTR1A
3 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSBBBG00000006724
Gene Symbol: HTR1B
3 Cross references
244 Possible Orthologues:

5-Hydroxytryptamine Receptor 1d

Ensembl ID : ENSBBBG00000000846
Gene Symbol: HTR1D
3 Cross references
67 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSBBBG00000021278
Gene Symbol: HTR1E
3 Cross references
157 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSBBBG00000003781
Gene Symbol: HTR1F
3 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSBBBG00000000488
Gene Symbol: HTR2A
3 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSBBBG00000025077
Gene Symbol: HTR2B
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSBBBG00000005652
Gene Symbol: HTR2C
1 Cross references
226 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSBBBG00000001979
Gene Symbol: HTR3A
3 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSBBBG00000011021
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSBBBG00000025179
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).